FDA's Review of Geron's Imetelstat Therapy Ahead of AdCom Meeting Leads to Market Reaction
Tuesday, 12 March 2024, 15:00
Summary:
Shares of Geron (GERN) declined after the FDA commented on its blood cancer therapy Imetelstat ahead of an advisory committee meeting later this week.
Key Points:
- Geron's stock slipped following FDA's comments on blood cancer therapy Imetelstat.
- The FDA's review comes ahead of an advisory committee meeting scheduled for this week, impacting market sentiment.
- Investors should monitor developments closely to assess the potential implications for Geron's future performance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.